FranΓ§aisπ See the interactive version (live chart) β
For UiPath, we replayed every analyst price target of the past 12 months and measured the real outcome: 25% were profitable, average return -21% (76 calls). At 3 months: -10% average return (22% profitable). The higher the %, the more often analysts were right on this stock.
Their past track record on this stock (targets replayed against real prices) β not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Needham | 10 | 30% | -21% |
| Wells Fargo | 8 | 50% | +5% |
| Truist Securities | 7 | 29% | -16% |
| Credit Suisse | 7 | 57% | +5% |
| Canaccord Genuity | 6 | 0% | -21% |
Is UiPath overvalued, and is it a good time to buy UiPath right now? If you're wondering, here's a recap to make up your own mind: UiPath's valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.
The P/E (price Γ· earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects β but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.
| Metric | UiPath | Sector median (Information Technology) |
|---|---|---|
| P/E | 27.8 | 39.4 |
| Forward P/E | 20.2 | 20.6 |
| Net margin | 20% | 16% |
π UiPath trades below its sector median (27.8 vs 39.4) β potentially undervalued, or lower expected growth.
π P/E, PEG, marginβ¦: see the glossary
The analyst consensus on UiPath (PATH) is "Hold" (5 bullish, 2 bearish calls over 12 months). This is not advice: historically, 25% of their targets on this stock turned out profitable over 1 year.
The median 12-month price target is $13.00 (-29% vs $18.33), ranging from $12.00 to $15.00 (12 analysts).
Over 1 year, 25% of analyst targets on UiPath were profitable, for an average return of -21% (across 76 timestamped calls). This is JPI Invest's accuracy metric.
Analysts target a median of $13.00 within 12 months, i.e. -29% vs the current price. The most bullish targets $15.00, the most cautious $12.00.
Note: analyst targets are 12-month (median $13.00, -29%), NOT 2030. No reliable 5-10 year price forecast exists (Β« 2030 prediction Β» models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (25%), and the stock's past trajectory.
Its P/E is 27.8, forward P/E 20.2. A forward P/E lower than the current P/E means earnings are expected to grow.
π See the full interactive analysis of UiPath β
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
Explore JPI Invest for free β How it works: the method β
β οΈ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.